Evidence map›Paper›PMID 39026604›Full record

ArticleNon-coding RNA research2024

The role of exosomal lncRNAs in acetaminophen-induced induced liver injury in SD rats.

Zixuan Yang, Lei Shi, Minhui Zheng, Minbo Hou, Mengdi Zhou, Naying Su, Hui Lang, Liyuan Zhao, Mengyun Gu, Naping Tang and 1 more

Abstract read
In one paragraph

Article in Non-coding RNA research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zixuan YangChina State Institute of Pharmaceutical Industry, Shanghai, 201203, China.
Lei ShiChina State Institute of Pharmaceutical Industry, Shanghai, 201203, China.
Minhui ZhengChina State Institute of Pharmaceutical Industry, Shanghai, 201203, China.
Minbo HouShanghai Innostar Bio-Technology Co., Ltd, Shanghai, 201203, China.
Mengdi ZhouShanghai Innostar Bio-Technology Co., Ltd, Shanghai, 201203, China.
Naying SuShanghai Innostar Bio-Technology Co., Ltd, Shanghai, 201203, China.
Hui LangShanghai Innostar Bio-Technology Co., Ltd, Shanghai, 201203, China.
Liyuan ZhaoCollege of Pharmacy, Anhui University of Chinese Medicine, Hefei, Anhui, 230000, China.
Mengyun GuChina State Institute of Pharmaceutical Industry, Shanghai, 201203, China.
Naping TangChina State Institute of Pharmaceutical Industry, Shanghai, 201203, China.
Yan ChangChina State Institute of Pharmaceutical Industry, Shanghai, 201203, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Drug-induced liver injury (DILI) is a leading cause of drug development failures during clinical trials and post-market introduction. Current biomarkers, such as ALT and AST, lack the necessary specificity and sensitivity needed for accurate detection. Exosomes, which protect LncRNAs from RNase degradation, could provide reliable and easily accessible options for biomarkers. Materials and methods: RNA-sequencing was used to identify differentially expressed LncRNAs (DE-LncRNAs), followed by isolation of LncRNAs from plasma exosomes in this study. Exosome characterization was conducted by transmission electron microscopy (TEM), nanoparticle tracking analysis (NTA), and Western blot (WB). Bioinformatics analysis included functional enrichment and co-expression network analysis. Five rat models were established, and quantitative real-time PCR was used to verify the specificity and sensitivity of two candidate exosomal LncRNAs. Results: The APAP-induced hepatocellular injury model was successfully established for RNA-sequencing, leading to the identification of several differentially expressed exosomal LncRNAs. Eight upregulated exosomal DE-LncRNAs were selected for validation. Among them, NONRATT018001.2 (p < 0.05) and MSTRG.73954.4 (p < 0.05) exhibited a more than 2-fold increase in expression levels. In hepatocellular injury and intrahepatic cholestasis models, both NONRATT018001.2 and MSTRG.73954.4 showed earlier increases compared to serum biomarkers ALT and AST. However, no histological changes were observed until the final time point. In the fatty liver model, NONRATT018001.2 and MSTRG.73954.4 increased earlier than ALT and AST at 21 days. By the 7th day, minor steatosis was evident in liver tissue, while the expression levels of the two candidate exosomal LncRNAs exceeded 2 and 4 times, respectively. In the hepatic fibrosis model, NONRATT018001.2 and MSTRG.73954.4 showed increases at every time point. By the 49th day, hepatocellular necrosis and fibrosis were observed in the liver tissue, with NONRATT018001.2 showing an increase of more than 8 times. The specificity of the identified exosomal DE-LncRNAs was verified using a myocardial injury model and they showed no significant differences between the case and control groups. Conclusion: NONRATT018001.2 and MSTRG.73954.4 hold potential as biomarkers for distinguishing different types of organ injury induced by drugs, particularly enabling early prediction of liver injury. Further experiments, such as siRNA interference or gene knockout, are warranted to explore the underlying mechanisms of these LncRNAs.

Indexed as

DILIExosomeLncRNAPCRRNA sequencing

Identifiers

PMID39026604
PMCPMC11254842

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.